Contracts and Revenue Questions, page-16

I'm not confident the rank and file investor shares the the same belief re oppie expiry (zero impact for new investors outside of enjoying a potentially fruitful / news packed run) nor impending CR which is all speculation at this moment. I think the progress re distro ags and revenue, derma raw mat sales, nutra being given a shot in China, is at very least enough to sustain the recovered SP and some slow and steady growth. The pattern of the small down sells over the past weeks and now large scoop buys is not representative of the "market" as a whole - feels manipulated to me, hence the stumped.